Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder

CNS Spectrums

Volumn 20, Issue 1, 2015, Pages 1-6

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLIBANSERIN; GLUTAMIC ACID; NORADRENALIN; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; BENZIMIDAZOLES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

ARTICLE; BRAIN STEM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; LIBIDO; NEUROMODULATION; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PREFRONTAL CORTEX; PREMENOPAUSE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; REWARD; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEXUAL AROUSAL; SYNAPSE; BRAIN; DRUG EFFECTS; FEMALE; HUMANS; METABOLISM; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

BENZIMIDAZOLES; BRAIN; FEMALE; HUMANS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84925052238     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000832     Document Type: Article

References (25)

1. Georgiadis JR, Kringelbach ML. The human sexual response cycle: Brain imaging evidence linking sex to other pleasures. Prog Neurobiol. 2012; 98(1): 49-81.
2. Stahl SM. Illustrating the circuits of sexual desire. J Clin Psychiatry. 2010; 71(9): 1113-1114.
3. Stahl SM. Circuits of sexual desire in hypoactive sexual desire disorder. J Clin Psychiatry. 2010; 71(5): 518-519.
4. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009; 6(6): 1506-1533.
5. Woodard TL, Nowak NT, Balon R, Tancer M, Diamond MP. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: A cross sectional pilot study. Fertil Steril. 2013; 100(4): 1068-1076.
6. Arnow BA, Millheiser L, Garrett A, et al. Women with hypoactive sexual desire disorder compared to normal females: A functional magnetic resonance imaging study. Neuroscience. 2009; 158(2): 484-502.
7. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011; 8(1): 15-27.
8. Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry. 2010; 71(7): 821-822.
9. Gelez H, Greggain-Mohr J, Pfaus JG, Allers KA, Giuliano F. Flibanserin treatment increases appetitive sexual motivation in the female rat. J Sex Med. 2013; 10(5): 1231-1239.
10. Gelez H, Clement P, Compagnie S, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013; 230(4): 639-652.
11. Aubert Y, Gustison ML, Gardner LA, et al. Flibanserin and 8-OHDPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality. J Sex Med. 2012; 9(3): 694-707.
12. Stahl SM. The last Diagnostic and Statistical Manual (DSM): Replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 65-68.
13. Insel T, Cuthbert B, Garvey M, et al. Research Domain Criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167(7): 748-751.
14. Goto Y, Grace AA. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci. 2005; 8: 805-813.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
16. Clayton AH, Goldfischer E, Goldstein I, et al. Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder. J Sex Marital Ther. 2013; 39(2): 132-143.
17. Stahl SM. The psychopharmacology of sex, Part 1: Neurotransmitters and the 3 phases of the human sexual response. J Clin Psychiatry. 2001; 62(2): 80-81.
18. Stahl SM. The psychopharmacology of sex, Part 2: Effects of drugs and disease on the 3 phases of human sexual response. J Clin Psychiatry. 2001; 62(3): 147-148.
19. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM. Open label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012; 9(12): 3180-3188.
20. DeRogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET study. J Sex Med. 2012; 9(4): 1074-1085.
21. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study. J Sex Med. 2012; 9(3): 793-804.
22. Goldfischer ER, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): Results from a randomized withdrawal trial. J Sex Med. 2011; 8(11): 3160-3172.
23. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the SNOWDROP trial. Menopause. 2014; 21(6): 633-640.
24. Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial. J Sex Med. 2013; 10(7): 1807-1815.
25. Bortolozzi A, Masana M, Díaz-Mataix L, et al. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5HT(1A) receptors but not 5HT(2A) receptors. Int J Neuropsychopharmacol. 2010; 13(10): 1299-1314. 6